CINCINNATI--(BUSINESS WIRE)--Jun. 25, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO) (“Aerpio”) today announced
that it intends to sell, subject to market and other conditions, $40
million of its common stock in an underwritten public offering. Aerpio
also intends to grant the underwriters a 30-day option to purchase an
additional fifteen percent (15%) of the shares of its common stock
offered in the public offering. Aerpio also announced that its common
stock has been approved for listing on the Nasdaq Capital Market,
subject to the pricing of the public offering on the terms proposed.
Guggenheim Securities is acting as book-running manager for the
offering. Needham & Company is acting as lead manager, and National
Securities Corporation and H.C. Wainwright & Co. are acting as
co-managers for the offering.
Aerpio intends to use the net proceeds from the offering for working
capital and general corporate and administrative purposes.
The securities described above are being offered by Aerpio pursuant to a
shelf registration statement on Form S-3 (No. 333-223113), including a
base prospectus. The securities will be offered only by means of a
prospectus. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and will
be available on the SEC’s website located at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus may also be obtained, when available, from: Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th
Floor, New York, NY 10017, or by telephone at (212) 518-9658, or by
email to GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy.
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the completion of
the proposed offering, the use of proceeds from the proposed offering
and uplisting of Aerpio’s common stock to the Nasdaq Capital Market. All
such forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties related to fluctuations in our
stock price, changes in market conditions and satisfaction of customary
closing conditions related to the public offering, as well as the other
factors discussed in the “Risk Factors” section in Aerpio’s most
recently filed Annual Report on Form 10-K, as well as other risks
detailed in Aerpio’s subsequent filings with the Securities and Exchange
Commission. There can be no assurance that Aerpio will be able to
complete the proposed public offering on the anticipated terms. All
information in this press release is as of the date of the release, and
Aerpio undertakes no duty to update this information unless required by
View source version on businesswire.com: https://www.businesswire.com/news/home/20180625006117/en/
Source: Aerpio Pharmaceuticals, Inc.
Investors & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.